Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026)
Recursion Pharmaceuticals (RXRX) posted Gross Margin of 92.99% for Q1 2026, down 255.41% on a QoQ basis from 59.83% in Q4 2025, and down 4494.0% year-over-year from 2.12% in Q1 2025.
Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 92.99% for Q1 2026.
- Quarterly Gross Margin fell 4494.0% year-over-year to 92.99% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.22% (up 72.0% YoY) and the FY2025 annual result came in at 4.99%, down 1812.0% from the prior year.
- Gross Margin was 92.99% for Q1 2026 at Recursion Pharmaceuticals, down from 59.83% in the prior quarter.
- Across five years, Gross Margin topped out at 59.83% in Q4 2025 and bottomed at 183.81% in Q3 2025.
- A 5-year average of 26.59% and a median of 3.27% in 2023 frame the typical range for Gross Margin.
- Peak annual rise in Gross Margin reached 24127 bps in 2025, while the deepest fall reached 23750 bps in 2025.
- Recursion Pharmaceuticals' Gross Margin stood at 20.74% in 2022, then tumbled by 55 bps to 9.27% in 2023, then tumbled by 2056 bps to 181.43% in 2024, then soared by 133 bps to 59.83% in 2025, then sank by 255 bps to 92.99% in 2026.
- Business Quant data shows RXRX's Gross Margin at 92.99% in Q1 2026, 59.83% in Q4 2025, and 183.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -92.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.99% |
| Dec 31, 2025 | 59.83% |
| Sep 30, 2025 | -183.81% |
| Jun 30, 2025 | -4.88% |
| Mar 31, 2025 | -48.04% |
| Dec 31, 2024 | -181.43% |
| Sep 30, 2024 | 53.69% |
| Jun 30, 2024 | 36.19% |
| Mar 31, 2024 | 19.05% |
| Dec 31, 2023 | 9.27% |
| Sep 30, 2023 | -3.27% |
| Jun 30, 2023 | 14.84% |
| Mar 31, 2023 | -2.59% |
| Dec 31, 2022 | 20.74% |
| Sep 30, 2022 | -17.09% |
| Jun 30, 2022 | -85.39% |
| Mar 31, 2022 | -46.24% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |